Van ECK Associates Corp Buys 3,066 Shares of Repligen Co. (NASDAQ:RGEN)

Van ECK Associates Corp grew its stake in shares of Repligen Co. (NASDAQ:RGEN) by 7.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 42,226 shares of the biotechnology company’s stock after acquiring an additional 3,066 shares during the period. Van ECK Associates Corp owned 0.08% of Repligen worth $6,078,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in RGEN. Champlain Investment Partners LLC raised its stake in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Repligen by 79.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock valued at $65,395,000 after buying an additional 203,011 shares during the last quarter. DF Dent & Co. Inc. raised its stake in Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares during the last quarter. Two Sigma Advisers LP raised its stake in Repligen by 421.9% during the third quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock valued at $18,796,000 after buying an additional 102,100 shares during the last quarter. Finally, Fred Alger Management LLC raised its stake in shares of Repligen by 29.5% in the third quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company’s stock worth $59,313,000 after purchasing an additional 90,831 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. HC Wainwright decreased their price target on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. TD Cowen initiated coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $182.91.

Repligen Stock Performance

NASDAQ RGEN opened at $146.92 on Tuesday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The business’s 50-day moving average price is $155.26 and its 200 day moving average price is $148.82. The firm has a market cap of $8.23 billion, a P/E ratio of -397.07, a P/E/G ratio of 4.54 and a beta of 0.99.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.